Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 30, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Predictive molecular classifiers in colorectal cancer.

Pierre Bohanes¹, Melissa J LaBonte, Thomas Winder

¹Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.

Seminars in Oncology

|August 4, 2011

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Genetic Variation and Regulation of MICA Alters Natural Killer Cell-Mediated Immunosurveillance in Early-Onset Colorectal Cancer.

medRxiv : the preprint server for health sciences·2024

Same author

Large-scale analysis of CDH1 mutations defines a distinctive molecular subset with treatment implications in gastric cancer.

NPJ precision oncology·2024

Same author

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.

Cancer chemotherapy and pharmacology·2024

Same author

Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.

British journal of cancer·2024

Same author

Plant-based diet and survival among patients with metastatic colorectal cancer.

Journal of the National Cancer Institute·2024

Same author

Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review.

Cancers·2024

KRAS mutation is a key predictor for anti-EGFR therapy in colorectal cancer (CRC). This review summarizes important predictive molecular markers, including BRAF, PI3KCA, and PTEN, for CRC treatment efficacy.

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Predictive molecular markers significantly improve patient selection for targeted therapies.
KRAS mutation is a well-established marker for anti-EGFR antibody efficacy in colorectal cancer (CRC).
Emerging markers like BRAF, PI3KCA, and PTEN also show potential in predicting treatment response.

Purpose of the Study:

To review key predictive molecular classifiers in colorectal cancer (CRC).
To discuss conflicting findings regarding these molecular markers.
To enhance understanding of personalized medicine in CRC treatment.

Main Methods:

Literature review of studies on predictive markers in colorectal cancer.
Analysis of data on KRAS, BRAF, PI3KCA mutations, and PTEN expression.

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Synthesis of evidence on marker efficacy and treatment outcomes.

Main Results:

KRAS mutation remains the primary marker for anti-EGFR therapy in CRC.
BRAF mutations, PI3KCA mutations, and PTEN loss are also relevant predictors.
Evidence for other markers and their impact on cytotoxic agents is under investigation.

Conclusions:

Accurate identification of predictive markers is crucial for optimizing CRC treatment.
Further research is needed to resolve conflicting data on various molecular classifiers.
Personalized treatment strategies based on molecular profiling are essential for improving CRC patient outcomes.